COSTA MESA, CA--(Marketwire - June 23, 2009) - CNS Response, Inc. (OTCBB: CNSO) today announced the closing of a $1 million dollar bridge loan with venture capitalist John Pappajohn.

"This financing comes at a critical time for CNS Response, providing both the resources to complete the treatment-resistant depression trial and drive wider clinical use of Referenced-EEG®," stated George Carpenter, Chief Executive Officer of CNS Response. "John Pappajohn has financed numerous healthcare companies, from Caremark to Quantum Health, and has introduced many healthcare innovations through his commercialization expertise and financial leadership."

Over the past two months the company has obtained two bridge loans totaling $1.2 million. Details pertaining to the bridge loans are available in the Form 8-Ks filed with the SEC.

CNS Response also announced that it has completed enrollment at 14 study sites for its treatment-resistant depression (TRD) clinical trial. This puts the company on track to complete the trial in September and release top-line results before year-end.

"Completion of our clinical trial is an important milestone for CNS Response," said President and Chief Medical Officer Daniel Hoffman. "Physicians using Referenced-EEG are achieving better patient outcomes and, according to the United BioSource study, Referenced-EEG already offers superior evidence for treatment-resistant depression. Our current clinical trial will bring this technology to the attention of the nation's top academic and clinical psychiatrists."

About CNS Response

Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

CNS Response has developed a patented data-analysis capability that, with the help of a simple, non-invasive EEG, will analyze a patient's brain waves and compare the results to an extensive patient outcomes database. The process produces an rEEG® report providing a psychiatrist with guidance to personalize medication regimens for a patient, based on the patient's own brain physiology. To read more about the benefits this patented technology provides physicians, patients and insurers, please visit the CNS Response website, www.cnsresponse.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.